Visão geral da empresa
A performance beauty company, Evolus, Inc. focuses on delivering products specifically within the cash-pay aesthetic market across the United States, Canada, Europe, and Australia. The company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry, where it specializes in proprietary formulations for temporary cosmetic improvements. According to the latest available data, the firm employs 334 individuals and holds a market capitalization of $275.85M. The annual revenue generated over the trailing twelve months reaches $297.18M, indicating a substantial operational footprint for a mid-sized entity in the specialty drug manufacturing space. These valuation figures suggest the company maintains a significant presence in its niche, balancing the high fixed costs typical of pharmaceutical development with a global distribution network that spans multiple continents.
Saúde financeira
The company reports revenue of $297.18M for the trailing twelve months, while the net income stands at a loss of $-51,641,000 and EBITDA is recorded at $-30,094,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure where operating expenses, likely driven by research, development, and general administrative costs, heavily outweigh current profitability. Free cash flow is reported at $-26,697,750, which indicates that the company is currently utilizing its cash reserves to fund operations and strategic initiatives rather than generating surplus cash from core business activities. Gross margin stands at 66.3%, reflecting a highly efficient production process or high pricing power for its specialized products, yet this does not translate to bottom-line profitability at this stage. Operating margin is -0.3% and profit margin is -17.4%, illustrating that despite strong gross efficiency, overhead costs are eroding operating income significantly before taxes and interest. The balance sheet shows cash of $53.83M against total debt of $155.00M, and the debt-to-equity ratio is listed as N/A, suggesting a leveraged position where liabilities exceed liquid assets without a traditional equity buffer to offset the debt. The current ratio is 1.90, which indicates that the company possesses sufficient current assets to cover its short-term obligations with a comfortable margin of safety. Return on Equity is N/A due to the negative equity position, while Return on Assets is -10.3%, revealing that the company's asset base is currently generating a negative return relative to the capital invested.
Avaliação de valorização
The P/E Ratio (TTM) is N/A because the company is currently unprofitable, while the forward P/E is 17.67, which implies market expectations for future earnings normalization despite current losses. The price-to-book ratio is -11.94, indicating that the market is valuing the company at a negative multiple of its book value, a metric often seen in capital-intensive or loss-making pharmaceutical firms. The price-to-sales ratio is 0.93, and the EV/EBITDA is -12.53, suggesting that valuation is currently driven by revenue multiples and future cash flow expectations rather than current earnings or equity value. The 52-week high is $12.28 and the 52-week low is $3.86, meaning the current trading price sits within this established volatility range, reflecting recent market sentiment regarding the company's turnaround potential. The beta is 1.00, which indicates that the stock price volatility matches the broader market average, suggesting it does not exhibit extreme sensitivity to market-wide fluctuations compared to high-beta or low-beta peers.
Growth & Income
Revenue growth over the last year is 14.4%, while earnings growth is N/A due to the company's current unprofitable status. Since the earnings growth rate cannot be calculated against a positive earnings baseline, the focus remains on the robust expansion of the top line, which implies successful market penetration or price increases for its aesthetic products. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. Instead of paying dividends, the firm retains all earnings, though currently negative, to reinvest into research, manufacturing capacity, and market expansion within the aesthetic medicine sector. The overall growth and income profile is characterized by strong top-line expansion funded by retained cash reserves, with no current income generation from dividends or earnings to support shareholder distributions.